ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing

Therese E. Gadomski, Melody Bolton, Majid Alfadhel, Chris Dvorak, Olalekan A. Ogunsakin, Stephen L. Nelson, Eva Morava-Kozicz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

ALG13-CDG has been recently discovered as a disorder of severe developmental, intellectual and speech disability, microcephaly, visual abnormalities, seizures, hepatomegaly, coagulation abnormalities, and abnormal serumtransferrin isoelectric focusing in serum. A male with seizures, delayed motor, and speech development, but normal cognition carried a hemizygous, predicted pathogenic ALG13 variant (p.E463G). N-glycosylation studies in plasma were normal. ICAM-1 expression was decreased in patient fibroblasts, supporting the variant's pathogenicity. Adding D-galactose to the patient's fibroblast culture increased ICAM-1 expression in vitro, offering a potential treatment option in ALG13-CDG. The present report is a new example for an N-glycosylation disorder, that may present with normal transferrin isoform analysis, and also demonstrates, that CDG type I patients can have normal cognitive development.

Original languageEnglish (US)
Pages (from-to)2772-2775
Number of pages4
JournalAmerican Journal of Medical Genetics, Part A
Volume173
Issue number10
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Isoelectric Focusing
Transferrin
Seizures
Intercellular Adhesion Molecule-1
Glycosylation
Fibroblasts
Microcephaly
Hepatomegaly
Galactose
Intellectual Disability
Cognition
Virulence
Protein Isoforms
Serum
Therapeutics

Keywords

  • galactose
  • glycosylation
  • ICAM-1
  • normal TIEF
  • seizures

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing. / Gadomski, Therese E.; Bolton, Melody; Alfadhel, Majid; Dvorak, Chris; Ogunsakin, Olalekan A.; Nelson, Stephen L.; Morava-Kozicz, Eva.

In: American Journal of Medical Genetics, Part A, Vol. 173, No. 10, 01.10.2017, p. 2772-2775.

Research output: Contribution to journalArticle

Gadomski, Therese E. ; Bolton, Melody ; Alfadhel, Majid ; Dvorak, Chris ; Ogunsakin, Olalekan A. ; Nelson, Stephen L. ; Morava-Kozicz, Eva. / ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing. In: American Journal of Medical Genetics, Part A. 2017 ; Vol. 173, No. 10. pp. 2772-2775.
@article{dbb3aa7039c349d986a67a43f6815a2d,
title = "ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing",
abstract = "ALG13-CDG has been recently discovered as a disorder of severe developmental, intellectual and speech disability, microcephaly, visual abnormalities, seizures, hepatomegaly, coagulation abnormalities, and abnormal serumtransferrin isoelectric focusing in serum. A male with seizures, delayed motor, and speech development, but normal cognition carried a hemizygous, predicted pathogenic ALG13 variant (p.E463G). N-glycosylation studies in plasma were normal. ICAM-1 expression was decreased in patient fibroblasts, supporting the variant's pathogenicity. Adding D-galactose to the patient's fibroblast culture increased ICAM-1 expression in vitro, offering a potential treatment option in ALG13-CDG. The present report is a new example for an N-glycosylation disorder, that may present with normal transferrin isoform analysis, and also demonstrates, that CDG type I patients can have normal cognitive development.",
keywords = "galactose, glycosylation, ICAM-1, normal TIEF, seizures",
author = "Gadomski, {Therese E.} and Melody Bolton and Majid Alfadhel and Chris Dvorak and Ogunsakin, {Olalekan A.} and Nelson, {Stephen L.} and Eva Morava-Kozicz",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/ajmg.a.38377",
language = "English (US)",
volume = "173",
pages = "2772--2775",
journal = "American Journal of Medical Genetics, Part A",
issn = "0148-7299",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing

AU - Gadomski, Therese E.

AU - Bolton, Melody

AU - Alfadhel, Majid

AU - Dvorak, Chris

AU - Ogunsakin, Olalekan A.

AU - Nelson, Stephen L.

AU - Morava-Kozicz, Eva

PY - 2017/10/1

Y1 - 2017/10/1

N2 - ALG13-CDG has been recently discovered as a disorder of severe developmental, intellectual and speech disability, microcephaly, visual abnormalities, seizures, hepatomegaly, coagulation abnormalities, and abnormal serumtransferrin isoelectric focusing in serum. A male with seizures, delayed motor, and speech development, but normal cognition carried a hemizygous, predicted pathogenic ALG13 variant (p.E463G). N-glycosylation studies in plasma were normal. ICAM-1 expression was decreased in patient fibroblasts, supporting the variant's pathogenicity. Adding D-galactose to the patient's fibroblast culture increased ICAM-1 expression in vitro, offering a potential treatment option in ALG13-CDG. The present report is a new example for an N-glycosylation disorder, that may present with normal transferrin isoform analysis, and also demonstrates, that CDG type I patients can have normal cognitive development.

AB - ALG13-CDG has been recently discovered as a disorder of severe developmental, intellectual and speech disability, microcephaly, visual abnormalities, seizures, hepatomegaly, coagulation abnormalities, and abnormal serumtransferrin isoelectric focusing in serum. A male with seizures, delayed motor, and speech development, but normal cognition carried a hemizygous, predicted pathogenic ALG13 variant (p.E463G). N-glycosylation studies in plasma were normal. ICAM-1 expression was decreased in patient fibroblasts, supporting the variant's pathogenicity. Adding D-galactose to the patient's fibroblast culture increased ICAM-1 expression in vitro, offering a potential treatment option in ALG13-CDG. The present report is a new example for an N-glycosylation disorder, that may present with normal transferrin isoform analysis, and also demonstrates, that CDG type I patients can have normal cognitive development.

KW - galactose

KW - glycosylation

KW - ICAM-1

KW - normal TIEF

KW - seizures

UR - http://www.scopus.com/inward/record.url?scp=85028382181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028382181&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.38377

DO - 10.1002/ajmg.a.38377

M3 - Article

VL - 173

SP - 2772

EP - 2775

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 0148-7299

IS - 10

ER -